18 Sep 2025 | 5 Mins Read
Wegovy pill offers significant weight loss, Novo Nordisk says
Flipitmoney
Novo Nordisk's once-daily obesity pill, an oral version of Semaglutide, showed a 16.6% average weight reduction in a 64-week phase 3 trial. The pill, a potential alternative to Novo's Wegovy injectable, has similar efficacy and tolerability. Currently under FDA review, a decision is expected in Q4. The oral treatment will be made in the U.S. if approved.